Evidence map›Paper›PMID 39564715›Full record

ArticleMovement disorders clinical practice2025

Association of Hemispheric Asymmetry of Dopamine-Transporter Binding with Risk of Parkinsonian Depression.

Emilio Fernández-Espejo, Fernando Rodríguez de Fonseca

Abstract read
In one paragraph

Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emilio Fernández-EspejoRoyal College of Physicians of Seville, Sevilla, Spain.ORCID 0000-0003-0724-6049
Fernando Rodríguez de FonsecaInstituto de Investigación Biomédica de Málaga and Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain.

Funding

Consejería de Salud y Consumo, Junta de Andalucía Neuro-RECA-RIC-0111-2019Instituto de Salud Carlos III ERDF-EU-RD21/0009/0003Instituto de Salud Carlos III PI22/00427Ministerio de Ciencia e Innovación, Gobierno de España ERDF-EUMinisterio de Ciencia e Innovación, Gobierno de España RTC2019-007329-1Ministerio de Sanidad, Gobierno de EspañaSociedad Andaluza de Neurología SUBAIA2015/006
6 · The paper itself

Abstract

backgroundDepression is the most common psychiatric disorder diagnosed in patients with Parkinson's disease (PD). A direct role in PD depression for loss of dopaminergic terminals and dopamine-transporter (DAT) expression in the striatum is revealed by many studies.

objectivesThe objective was to discern the relationship between DAT neuroimaging and risk of depression in PD.

methodsOne hundred and ninety-eight PD patients (101 with depression, 97 without depression) were evaluated using an extensive protocol from 2015 to 2023. DAT availability at striatal terminals was assessed with single-photon emission computed tomography with

resultsA logistic regression model adjusting for confounding risk factors of depression indicates that SASI and PD duration are associated with the odds of having parkinsonian depression. SASI is the strongest predictor of risk of parkinsonian depression. Following ROC analysis, SASI is found to be an accurate factor for detecting parkinsonian depression because a cutoff value of 3.4895 of SASI shows good accuracy (0.813), sensitivity (81.1%), and specificity (80%). Higher SASI is also linked to more disease-related limitations in activities of daily living.

conclusionThe whole SASI is the strongest predictor of risk of parkinsonian depression. The findings could be valuable in evaluating depression in PD patients.

Indexed as

Corpus StriatumDepressionDopamine Plasma Membrane Transport ProteinsParkinson DiseaseAgedFemaleHumansMaleMiddle AgedNortropanesTomography, Emission-Computed, Single-PhotonDopamine Plasma Membrane Transport ProteinsioflupaneNortropanesasymmetrydepressiondopamine transporterParkinson's diseaseSPECT

Identifiers

PMID39564715
PMCPMC11952951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.